Medtronic (MDT), Why Is It Getting Fresh Attention Today?

Medtronic (MDT) is back in focus after fresh real-world registry data on its Affera Mapping and Ablation System and PulseSelect pulsed field ablation platform highlighted high acute success and low complication rates in complex arrhythmia patients.

Medtronic’s recent real-world data hit alongside a strong price run, with a 30-day share price return of 11.88% and a 90-day gain of 13.06%, suggesting momentum has picked up again after a relatively flat year-to-date move. Over a longer horizon, total shareholder return of 9.97% over one year and 46.79% over three years contrasts with a 5-year total shareholder return that is down 7.89%. The registry results and leadership changes in October 2026 therefore come at a moment when sentiment has been rebuilding rather than starting from scratch.

Scan how Medtronic’s registry-driven momentum compares with other device makers by screening for 34 healthcare AI stocks that could be riding similar real-world data catalysts.

Medtronic’s share price has perked up as registry data lands and leadership shifts settle in. Is this move finally mirroring the underlying business or just sentiment snapping back, and what does that imply for valuation next?

Most Popular Narrative: 16% Undervalued

Medtronic closed at $96.54 while the most followed narrative on the stock pegs fair value at $115.38. This frames the current move as a discount rather than a stretch. That gap sets the context for a thesis built around execution in key franchises and a management team trying to prove this is more than a short burst of enthusiasm.

Medtronic's fiscal first quarter of 2027 arrived with 13.7% organic growth, a number that would be arresting in any quarter, inflated here by an extra selling week management estimates contributed roughly 670 basis points. Strip the calendar effect and the underlying figure still represents, by their own account, the strongest performance in nearly eight years. The question this quarter is less about whether the machine is working than about what it is being asked to carry, a handful of narratives that management has been building for two years, now facing the moment where early innings must begin to feel less early.

See why 8 investors see Medtronic as 16% undervalued.

According to LunaRodas, who authored the widely tracked narrative, this gap between price and fair value reflects confidence that Medtronic's execution in cardiac ablation, structural heart and diabetes separation can support that $115.38 figure over time. For readers, the key question is whether the current $96.54 level already embeds those expectations or still leaves room if the outlined plans continue to play out as described.

Result: Fair Value of $115.38 (UNDERVALUED)

Still, Medtronic’s story can break if high profile programs like Hugo robotics or the MiniMed separation fail to meet execution and timing expectations.

Find out about the key risks to this Medtronic narrative.

Next Steps

Feeling encouraged by the tone of Medtronic’s story so far, or cautious about how much is already priced in? Either way, move quickly to review the underlying positives yourself and pressure test the thesis against the 5 key rewards.

Looking for more Medtronic style investment ideas?

If Medtronic has sharpened your appetite for clear stories backed by data, do not stop here. Broaden your watchlist now with focused, high quality ideas.

• Target potential mispricings by scanning a 29 high quality undervalued stocks that filters for strong fundamentals at prices that may not fully reflect them yet.
• Strengthen your income stream by running through a 5 dividend fortresses that focuses on companies offering yields of 5% or higher with an emphasis on resilience.
• Prioritize resilience first by using a 30 resilient stocks with low risk scores that highlights businesses with sturdier balance sheets and lower risk scores so downside does not catch you off guard.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com